Lilly Stops Antibody Trial in Hospitalized COVID-19 Patients

 Lilly Stops Antibody Trial in Hospitalized COVID-19 Patients

The business mentioned brand-new information from the NIH showing no substantial benefit for bamlanivimab in combination with remdesivir for people hospitalized with COVID-19 Medscape Medical News
Read More

Redak staff

Leave a Reply

Your email address will not be published.